Comment from Myotonic Dystrophy Foundation
AnonymousSupportAdvocacy
Summary: Tanya Stevenson, CEO of the Myotonic Dystrophy Foundation, supports the FDA's efforts to improve the patient-focused drug development (PFDD) process. She emphasizes the importance of incorporating patient preference data and first-hand experiences into the drug development pipeline for rare diseases like myotonic dystrophy.
Myotonic Dystophy Foundation Public Comment on Docket (FDA-2026-N-3947) Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments